Biomoda Awarded Patent in Mexico
June 07, 2010 07:13 AM Eastern Daylight Time
ALBUQUERQUE, N.M.--(EON: Enhanced Online News)--Cancer diagnostics company Biomoda, Inc. (OTCBB:
BMOD) (www.biomoda.com) has been granted a Mexican patent for its proprietary porphyrin-based compound
that binds to cancer cells and causes them to fluoresce red under ultraviolet light.
Issued by the Instituto Mexicano de la Propiedad Industrial (IMPI), Mexican patent #269352, “Compositions and
Methods for Detecting Pre-Cancerous Conditions In Cell And Tissue Samples Using 5, 10, 15, 20-Tetrakis
(Carboxyphenol) Porphine,” is similar to Biomoda’s U.S. patent 6,838,248, which was issued in 2005. Foreign
equivalents are now effective in Mexico, Japan and Australia and are pending in Europe and Canada.
“This patent represents another step in protecting our intellectual property rights internationally,” said Biomoda
President John Cousins. "We are strategically building our IP portfolio with an eye on the eventual commercialization
and marketing of our CyPath® diagnostic assay to address the global issue of lung cancer mortality.”
The 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine, or TCPP, is the foundation for several Biomoda product lines
and medical diagnostics. The company is concluding Phase II clinical trials of its first product, an in-vitro test for the
detection of early-stage lung cancer, in which study volunteers provide deep-lung sputum samples to be screened for
cancer cells with the CyPath® assay. Results are compared to CT scans and Pap stains read by independent
radiologists and cytopathologists, respectively, to confirm accuracy.
Biomoda is seeking Food and Drug Administration (FDA) approval of its cytology-based screening technology as a
Class III medical device. Pending FDA approval, CyPath® is for investigational use only.
Based, in Albuquerque, N.M., Biomoda is a cancer diagnostics company focused on the development of accurate,
inexpensive and noninvasive tests for the early detection of ca